Yarrow Bioscience/$YARW
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Yarrow Bioscience
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
- Ticker
- $YARW
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 7
- Headquarters
- New York, United States
- Website
- www.yarrowbioscience.com
YARW Metrics
BasicAdvanced
$168M
-
-$66.82
2.08
$0.40
2.23%
Price and volume
Market cap
$168M
Beta
2.08
52-week high
$44.28
52-week low
$12.39
Average daily volume
159K
Dividend rate
$0.40
Financial strength
Current ratio
1.398
Quick ratio
1.398
Profitability
Management effectiveness
Valuation
Price to book
-1.08
Price to tangible book (TTM)
-1.08
Price to free cash flow (TTM)
136.987
Free cash flow yield (TTM)
0.73%
Free cash flow per share (TTM)
0.132
Dividend yield (TTM)
2.23%
Growth
YARW Earnings Performance
Company profitability
Upcoming events
No upcoming events
YARW News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.